Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial protein hyperacetylation in the failing heart
Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly
Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly
View: Text | PDF
Research Article Cardiology Metabolism

Mitochondrial protein hyperacetylation in the failing heart

  • Text
  • PDF
Abstract

Myocardial fuel and energy metabolic derangements contribute to the pathogenesis of heart failure. Recent evidence implicates posttranslational mechanisms in the energy metabolic disturbances that contribute to the pathogenesis of heart failure. We hypothesized that accumulation of metabolite intermediates of fuel oxidation pathways drives posttranslational modifications of mitochondrial proteins during the development of heart failure. Myocardial acetylproteomics demonstrated extensive mitochondrial protein lysine hyperacetylation in the early stages of heart failure in well-defined mouse models and the in end-stage failing human heart. To determine the functional impact of increased mitochondrial protein acetylation, we focused on succinate dehydrogenase A (SDHA), a critical component of both the tricarboxylic acid (TCA) cycle and respiratory complex II. An acetyl-mimetic mutation targeting an SDHA lysine residue shown to be hyperacetylated in the failing human heart reduced catalytic function and reduced complex II–driven respiration. These results identify alterations in mitochondrial acetyl-CoA homeostasis as a potential driver of the development of energy metabolic derangements that contribute to heart failure.

Authors

Julie L. Horton, Ola J. Martin, Ling Lai, Nicholas M. Riley, Alicia L. Richards, Rick B. Vega, Teresa C. Leone, David J. Pagliarini, Deborah M. Muoio, Kenneth C. Bedi Jr., Kenneth B. Margulies, Joshua J. Coon, Daniel P. Kelly

×

Figure 4

Evidence for altered NAD+ homeostasis in failing mouse and human heart.

Options: View larger image (or click on image) Download as PowerPoint
Evidence for altered NAD+ homeostasis in failing mouse and human heart.
...
(A) NAD+ was measured in mouse cardiac tissue by quantitative mass spectrometry (n = 6/group). The values shown are normalized to mg of dry weight of tissue (mg dw). CH, compensated hypertrophy; HF, heart failure; TAC, transverse aortic constriction; MI, myocardial infarction. (B) Levels of NAD+, NADH, NAD phosphate (NADP+), and nicotinamide mononucleotide (NMN) in human failing (dilated cardiomyopathy [DCM]) and nonfailing (NF) control hearts (n = 5 per group). The values shown are normalized to mg of wet weight of tissue. (C) Schematic of NAD+ biosynthesis and salvage (within dashed line) pathways. NA, nicotinic acid; Naprt, nicotinate phosphoribosyltransferase; NaMN, NA mononucleotide; Nmnat, nicotinamide mononucleotide adenylyltransferase; Nadsyn, glutamine-dependent NAD+ synthetase; Nampt, nicotinamide phosphoribosyltransferase; Nmrk, nicotinamide riboside kinase 1;2; Nt5e, 5’-nucleotidase ecto; NR, nicotinamide riboside. *P < 0.05 based on Student’s t test. Bars represent mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts